Pelthos Appoints Andrew J. Einhorn to Board, Enhancing Financial Management
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Board Expansion: Pelthos Therapeutics has appointed veteran finance executive Andrew J. Einhorn to its Board of Directors, increasing the board size to eight members, aimed at leveraging his extensive capital markets experience to drive company growth.
- Financial Expertise Introduction: With over 40 years in investment banking and capital markets, and having served as CFO for multiple biotech firms, Einhorn is expected to provide strategic financial guidance that will support Pelthos's commercialization efforts.
- Audit and Compensation Committees: Einhorn will also serve on the Audit and Compensation Committees, enhancing the company's governance structure to ensure financial transparency and compliance, thereby boosting investor confidence.
- Future Outlook: Einhorn expressed confidence in Pelthos's future, believing the company has made a strong start as a newly public entity, and looks forward to collaborating with the Board to further advance the company's mission.
PTHS
$26.98+Infinity%1D
Analyst Views on PTHS
Wall Street analysts forecast PTHS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTHS is 66.00 USD with a low forecast of 57.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 26.760
Low
57.00
Averages
66.00
High
75.00
Current: 26.760
Low
57.00
Averages
66.00
High
75.00
About PTHS
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi (ozenoxacin) Cream, 1%, which is a non-fluorinated quinolone antimicrobial indicated for the topical treatment of impetigo. The Company is also evaluating the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
